Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$41.96M+457.56%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Daniel L. Reuvers
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 658
- Beta
- 1.20
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -3.43
Financials
Revenue
$41.96M+457.6%Net Income
$-1.69MEBITDA
$1.28MFree Cash Flow
$768.0KEPS (diluted)
$-0.02Shares Outstanding (diluted)
77.00M+686210.2%Operating Expenses
$21.35MCash & Debt
$22.11MRevenue by Segment (annual)
$149.16MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $149.16M | $-39.00M | $-0.59 |
| 2024 | $74.89M | $-43.71M | $-1.38 |
| 2023 | $71.35M | $-30.19M | $-1.05 |
| 2022 | $65.21M | $-37.16M | $-1.38 |
| 2021 | $55.31M | $-31.19M | $-1.22 |
| 2020 | $49.24M | $-27.45M | $-1.46 |
| 2019 | $62.66M | $-29.04M | $-1.87 |
| 2018 | $52.78M | $-24.10M | $-2.69 |
| 2017 | $40.43M | $-16.06M | $-1431.28 |
| 2016 | $34.23M | $-11.23M | $-1001.25 |
Valuation
STIMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
46-34.29%Social Signal Score
Mentions (13)
- Newszacks.com·3d ago·Neutral
Here's Why Neuronetics (STIM) is Poised for a Turnaround After Losing 37.8% in 4 Weeks Neuronetics (STIM) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
View source ↗ - Newsglobenewswire.com·4d ago·Positive
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced the granting of inducement award(s) to one non-executive employee as described below.
View source ↗ - Newszacks.com·5d ago·Neutral
Neuronetics (STIM) Loses 34.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Neuronetics (STIM) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
View source ↗ - Newsseekingalpha.com·18d ago·Positive
Neuronetics, Inc. (STIM) Q3 2026 Earnings Call Transcript Neuronetics, Inc. (STIM) Q3 2026 Earnings Call Transcript
View source ↗ - Newsglobenewswire.com·18d ago·Positive
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced the granting of inducement awards to fourteen non-executive employees as described below.
View source ↗ - Newsmarketbeat.com·18d ago·Positive
Neuronetics Q3 Earnings Call Highlights Neuronetics NASDAQ: STIM reported third-quarter 2026 revenue growth, wider gross margin and a return to positive adjusted EBITDA, citing record NeuroStar system sales and continued revenue-cycle improvements across its Greenbrook clinic network.
View source ↗ - Newszacks.com·18d ago·Negative
Neuronetics (STIM) Reports Q3 Loss, Tops Revenue Estimates Neuronetics (STIM) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.13 per share a year ago.
View source ↗ - Newsglobenewswire.com·18d ago·Positive
Neuronetics Reports Third Quarter 2026 Financial and Operating Results MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced its financial and operating results for the third quarter of 2026.
View source ↗ - Newsglobenewswire.com·32d ago·Positive
…tics to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call MALVERN, Pa., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced that it plans to release third quarter 2026 financial and operating results prior to market open on Wednesday, November 4, 2026.
View source ↗ - Newsglobenewswire.com·75d ago·Positive
…oStar Advances Practice Innovation with First-Ever TMS Integration with an EHR/EMR System MALVERN, Pa., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced the integration of its TrakStar® practice management platform with AdvancedMD, a leading cloud-based electronic health record (EHR), pr…
View source ↗ - Newsseekingalpha.com·103d ago·Positive
Neuronetics, Inc. (STIM) Q2 2026 Earnings Call Transcript Neuronetics, Inc. (STIM) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·103d ago·Neutral
Neuronetics Q2 Earnings Call Highlights Neuronetics NASDAQ: STIM reported second-quarter 2026 revenue growth, a sharply narrower net loss and positive adjusted EBITDA as its Greenbrook clinic business expanded and the company introduced additional commercial purchasing options for its NeuroStar transcranial magnetic stimulation, or TMS, systems.
View source ↗ - Newszacks.com·103d ago·Neutral
Neuronetics (STIM) Reports Q2 Loss, Beats Revenue Estimates Neuronetics (STIM) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.15 per share a year ago.
View source ↗
Earnings
Tue, Mar 16(in 4 months)
Consensus estimate $-0.09 per share
Typical surprise +5.9% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$-0.02 vs $-0.09beat
- Tue, Aug 11$-0.05 vs $-0.12beat
- Tue, May 5$-0.16 vs $-0.17beat
- Tue, Mar 17$-0.10 vs $-0.12beat
- Tue, Nov 4$-0.13 vs $-0.12miss
- Tue, Aug 5$-0.15 vs $-0.08miss
Estimates and results for STIM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by STIM officers and directors.
- Bought
- $4.9m
- Sold
- $18.6m
16 trades
24 trades
- Chernett Joreysold
- Chernett Joreysold
- Chernett Joreysold
- Chernett Joreybought
- Chernett Joreysold
- Chernett Joreysold
- Chernett Joreybought
- Chernett Joreybought
60 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in STIM.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
